Home/Pipeline/TimoD

TimoD

Glaucoma

Phase 1Active

Key Facts

Indication

Glaucoma

Phase

Phase 1

Status

Active

Company

EyeD Pharma

About EyeD Pharma

EyeD Pharma is a private, clinical-stage biotech based in Liège, Belgium, focusing on novel drug delivery for ophthalmology. Its core technology platform involves sustained-release polymeric micro-implants designed to enhance patient compliance and reduce side effects associated with traditional eye drop regimens. The pipeline includes programs for glaucoma (TimoD in Phase I), dry eye disease (HydraD in pre-clinical), and back-of-the-eye inflammation (InflammaD in feasibility), targeting large, growing patient populations. With over 100 employees and an internal CDMO, the company pursues a fully integrated development and manufacturing strategy.

View full company profile

Therapeutic Areas

Ophthalmology Glaucoma Dry Eye Disease Retinal Diseases

Other Glaucoma Drugs

Drug	Company	Phase	Status
PREZIA Glaucoma Implant	PolyActiva	Preclinical	Active
MIGS Device System	Micropoint Biotechnologies	Commercial	Market approved in China
INM-088	InMed Pharmaceuticals	Preclinical	Active
OT-401	Ocumension Therapeutics	Phase 2	Active
ANX007	Annexon Biosciences	Phase 2	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
hOTX2	BrainEver	Discovery	Active
Glaucoma Treatment	BVI Medical	Commercial	Active
MediPrint Lens (Glaucoma)	MediPrint Ophthalmics	Phase 2b	Active
Glaucoma Program	Broadwing Bio	Pre-clinical	Active
MSC Exosomal Eye Serum	Vitti Labs	Pre-clinical	Active
BTQ1902	Betaliq	Phase 2	Active